![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 31, 21507-21510, July 30, 1999
o with Rap1 GTPase-activating Protein*
§,
From the
Department of Pharmacology, Mount Sinai
School of Medicine, New York, New York 10029 and ¶ The Vollum
Institute, Oregon Health Sciences University, Portland, Oregon
97201
| |
ABSTRACT |
|---|
|
|
|---|
We used the yeast two-hybrid system to identify
proteins that interact directly with G Heterotrimeric G proteins function as signal transducers for
receptors for a large number of hormones, neurotransmitters, autocrine
and paracine factors, cytokines, and sensory signals. Both the G Materials--
The cDNA synthesis system was from Life
Technologies, Inc. Anti-G Yeast Two-hybrid Screening--
A directional oligo(dT)-primed
cDNA library was constructed from 12-day embryonic chick dorsal
root ganglion mRNA. cDNA was synthesized using a cDNA
synthesis system and ligated into the GAL4 DNA-activation domain
plasmid pPC86 using the SalI/NotI restriction sites (11).
Plasmid DNA was isolated from the unamplified library using a Qiafilter
Plasmid Maxi Kit. Q205L-G CPRG Assay--
The MaV203 yeast strain was co-transformed with
the GAL4 DNA-binding domain and GAL4 DNA activation domain plasmids as
indicated and incubated on selective media lacking tryptophan and
leucine for 3 days at 30 °C. Clones were grown for 24 h in
selective liquid media and then inoculated into complete media and
grown to an A600 of 1.5. Yeast were lyzed with
glass beads and incubated in a CPRG assay buffer (100 mM
HEPES, pH 7.3, 154 mM NaCl, 4.5 mM L-aspartate, 1% bovine serum albumin, and 0.05% Tween 20)
containing 2 mM CPRG (Roche Molecular Biochemicals) for
2-24 h. The reaction was stopped by the addition of ZnCl2
to 1 mM, and the absorbance was measured at 574 nM.
Co-immunoprecipitations--
HEK-293 cells were grown in
Dulbecco's modified Eagle's medium supplemented with 10% fetal
bovine serum and antibiotics. Cells were transfected using Effectene
and harvested after 48 h in Buffer A (50 mM HEPES, pH
7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 6 mM MgCl2, 10 µg/ml aprotinin, 10 µg/ml
leupeptin, and 1 mM phenylmethylsulfonyl fluoride). One mg
of whole cell lysate was pre-cleared for 1 h with protein
G-agarose at 4 °C. Immunoprecipitations were performed overnight
with 5 µg of M2-FLAG monoclonal antibody at 4 °C followed by a 4-h
incubation with 25 µl of protein G-agarose. Samples were washed three
times with phosphate-buffered saline (PBS) containing protease
inhibitors and then resolved using SDS-PAGE. After transfer to
nitrocellulose, the membranes were blocked in 5% nonfat dry milk,
immunoblotted with anti-M2-FLAG (1 µg/ml), anti-G RalGDS Assay--
PC-12 cells were grown in Dulbecco's modified
Eagle's medium, 10% horse serum, 5% fetal calf serum, 0.5%
glutamine and seeded at one million cells/10-cm dish. Cells were
transfected with 10 µg of FLAG-Rap1b (containing tandem FLAG epitopes
at the N terminus of the Rap1b cDNA) in pcDNA3 with or without
10 µg of wild type or the constitutively active versions of
G MAPK Immunoblots--
PC-12 cells were transfected with 10 µg
of Flag-MAPK2 (containing tandem FLAG epitopes at the N terminus of
MAPK2) in pcDNA3 with or without 10 µg of wild type or
constitutively active versions of G Using the yeast two-hybrid system, we screened the chick DRG
library with Q205L-G
o.
Mutant-activated G
o was used as the bait to screen a
cDNA library from chick dorsal root ganglion neurons. We found that
G
o interacted with several proteins including Gz-GTPase-activating protein (Gz-GAP), a new RGS protein (RGS-17), a
novel protein of unknown function (IP6), and Rap1GAP. This study focuses on Rap1GAP, which selectively interacts with G
o
and G
i but not with G
s or
G
q. Rap1GAP interacts more avidly with the unactivated
G
o as compared with the mutant (Q205L)-activated G
o. When expressed in HEK-293 cells, unactivated
G
o co-immunoprecipitates with the Rap1GAP. Expression of
chick Rap1GAP in PC-12 cells inhibited activation of Rap1 by forskolin.
When unactivated G
o was expressed, the amount of
activated Rap1 was greatly increased. This effect was not observed with
the Q205L-G
o. Expression of unactivated G
o stimulated MAP-kinase (MAPK1/2) activity in a
Rap1GAP-dependent manner. These results identify a novel
function of G
o, which in its resting state can sequester
Rap1GAP thereby regulating Rap1 activity and consequently gating signal
flow from Rap1 to MAPK1/2. Thus, activation of Go could
modulate the Rap1 effects on a variety of cellular functions.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(1)
and the G
subunits (2) are capable of transferring receptor
signals to effectors. There are four families of G
subunits (3).
Direct effectors for the G
s (4) and G
q
(5) family proteins have been well characterized. Effectors for the
G
i family are less well defined. G
t, the
visual G protein, activates the cGMP phosphodiesterase (1), and
G
i inhibits adenylyl cyclases (6) directly (7). However,
direct effectors for G
o, an abundant G protein in the
brain (8, 9), have not yet been identified. G
o has been
implicated in receptor-mediated inhibition of Ca2+ channels
in chick dorsal root ganglion neurons (10). Hence, it appeared feasible
that this system could be used to identify proteins that directly
interact with G
o. We used the yeast two-hybrid system to
identify potential G
o effectors. For this purpose, we
screened the chick dorsal root ganglion cDNA library with the mutationally (Q205L) activated form of G
o. In this
article we present data indicating that the inactive form of
G
o preferentially interacts with
Rap1GAP1 and thus regulates
the activity of the small G protein Rap.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
o and anti-MAPK2 antibodies
were from Santa Cruz Biotechnology, Anti-M2-FLAG antibody was from
Sigma, anti-G
I-3/o antibody was from Upstate
Biotechnology, Inc., and phospho-specific and total MAPK antibodies
were from New England Biolabs. Most biochemicals were from Sigma, and
cell culture supplies were from Life Technologies, Inc. All restriction
enzymes were from New England Biolabs. Yeast culture media and amino
acids were from CLONTECH. DNA plasmid preparation
reagents and Effectene and Superfect transfection reagents were from
Qiagen, Inc. ECL reagents were from Amersham Pharmacia Biotech. All
other reagents were of the highest grade available.
o was cloned into the
SalI/NotI restriction sites of the GAL4
DNA-binding domain plasmid pPC97-cycloheximide (11). The
Q205L-G
o-BD plasmid and the library were co-transformed
into the yeast strain MaV203, plated on selective media lacking
leucine, tryptophan, and histidine and containing 25 mM
3-aminotriazole, and incubated at 30 °C for 3 days. His+
colonies were then tested for
-galactosidase activity using a filter
lift assay. Plasmid DNA was then isolated from positive yeast clones
and reintroduced into MaV203 yeast expressing the GAL4 DNA-binding
domain in-frame with either the wild type or Q205L-G
o
cDNA. Positive clones were then sequenced, and BLAST analysis was
performed using GenBankTM. The G
q,
G
s, and G
i-2 cDNAs encoding both the
wild type and the constitutively activated mutants were subcloned into
the pPC97-cycloheximide plasmid.
o
(1:2000), or anti-G
i-3/o (1:2000) antibodies followed by
either rabbit or mouse HRP-conjugated secondary antibody. Bands were
visualized using the ECL detection method.
o or vector using Superfect per the manufacturer's
instructions. Twenty-four h after transfection, the medium was replaced
with low serum-containing media (0.1% horse serum) for 12 h.
Cells were treated with 10 µM forskolin/IBMX (3-isobutyl-1-methylxanthine) for 10 min, rinsed twice with ice-cold PBS, and lyzed in lysis buffer (10% glycerol, 1% Nonidet P-40, 50 mM Tris-HCl (pH 8.0), 200 mM NaCl, 2.5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 µM leupeptin, 10 µg/ml soybean trypsin
inhibitor, 10 mM NaF, 0.1 µM aprotinin, and 1 mM Na3VO4). Activated Rap1b was
isolated from cell lysates using a protocol adapted from Franke et al. (12). Lysates were clarified by centrifugation, and
supernatants containing 1 mg of total protein incubated with 60 µg of
Gst-RalGDS-Rap binding domain (Gst-RalGDS was a gift form Dr. Bos,
Utrecht University, The Netherlands to P. J. S. S.) pre-coupled to
glutathione beads. After a 1-h incubation at 4 °C, beads were
pelleted and rinsed three times with lysis buffer, and protein was
eluted from the beads using Laemmli buffer. Proteins were separated by
electrophoresis on a 12% gel followed by transfer to a polyvinylidene
difluoride membrane. Membranes were blocked in 5% milk for 1 h
and probed with the anti-M2-FLAG monoclonal antibody followed by an
HRP-conjugated anti-mouse monoclonal secondary antibody. Proteins were
detected by enhanced chemiluminescence. The transfection efficiency of FLAG-Rap1b and G
o plasmids was evaluated using 20 µg
of cell lysate by immunoblotting using anti-FLAG and
anti-G
o antibodies.
o, Rap1GAP, or
vector. Twenty-four h after transfection, the medium was replaced with
low serum-containing medium (0.1% horse serum) for 12 h. Cells
were stimulated with NGF (50 ng/ml) for 10 min, rinsed twice with
ice-cold PBS, and lyzed in MAPK lysis buffer (10% glycerol, 1%
Nonidet P-40, 50 mM Tris-HCl, pH 8.0, 137 mM
NaCl, 2 mM EDTA, pH 8.0, 1 mM
phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 10 µg/ml
aprotinin, 10 mM NaF, and 1 mM
Na3VO4). Five hundred µg of whole cell lysate
was immunoprecipitated for 2 h with 5 µg of M2-FLAG monoclonal
antibody pre-coupled to protein G-agarose. Samples were separated by
gel electrophoresis followed by transfer to a polyvinylidene difluoride
membrane. Membranes were blocked for 1 h in 5% milk and probed
with anti-phospho-MAPK antibody (1:1000), which is specific for the
active form of MAPK1/2, followed by mouse HRP-conjugated secondary
antibody (1:10,000). Proteins were visualized using ECL detection.
Controls for MAPK2 loading were performed using M2-FLAG monoclonal antibody.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
o as the bait. Initial screens
dorsal root ganglion positive interacting clones. Further analysis of
the true positive clones allowed us to identify four interacting
proteins in the initial screens. These proteins are listed in Table
I. The sequences for all of these
proteins have been submitted to GenBankTM, and the
accession numbers are listed in Table I. The first protein identified
was Gz-GAP, an RGS that has been characterized by other groups to
selectively regulate the GTPase activity of G
z (13, 14).
We also identified the cDNA clone for a hitherto unrecognized RGS
protein. We have named this protein RGS-17. Furthermore, we identified
a protein that does not appear to have functional homology with other
known proteins. However, it has a region that is similar to clone
called KIAA0514 in the human gene data base. These three clones at the
present time have not been studied any further in our laboratory. The
fourth G
o interacting protein we found was the chick
homologue of the human Rap1GAP (15). This interaction turned out to be
quite unusual and fascinating.
Results of G
o two-hybrid screen
Because we were interested in G
o effectors, we
hypothesized that such effectors would bind more avidly to the
activated form G
o than to the inactive wild type form.
To determine whether Rap1GAP interacted preferentially with
Q205L-G
o, we used a yeast two-hybrid assay. Much to our
surprise we found that Rap1GAP bound more avidly to the wild
type-G
o than to Q205L-G
o (Fig.
1A). The interaction of
Rap1GAP with G
o is specific, because no interactions were observed with either wild type or mutant activated
G
s or G
q. The Rap1GAP did interact with
G
i2, but only a small difference could be detected
between the active and inactive forms (Fig. 1B). We next
determined whether G
o and Rap1GAP interacted within the
context of a mammalian cell. For this determination, we tagged the
Rap1GAP with the FLAG epitope at the N terminus and co-expressed it
with wild type and Q205L-G
o in HEK-293 cells. Lysates
from the cells were immunoprecipated with the anti-M2-FLAG antibody; the immunoprecipitate was resolved by SDS-polyacrylamide gel
electrophoresis and blotted with an antibody against the carboxyl
terminus of G
i-3, which is specific for
G
i-3 and G
o. Whole cell lysates from
cells transfected with the empty FLAG vector did not show any
G
o in the immunoprecipitates, even though both the wild
type and activated G
o were being expressed (Fig.
2, left panels). However, when
the Rap1GAP was co-expressed, the wild type G
o was more
extensively imunoprecipitated than the Q205L-G
o. (Fig. 2, upper right panel). Rap1GAP also appears to interact with
a native protein in HEK-293 cells, which is either G
o or
G
i-3. This finding is not surprising because it
interacted with G
i-2 in the yeast two-hybrid assay. The
levels of Rap1GAP in the immunoprecipitates are very similar (Fig. 2,
middle right panel) as are the levels of expressed
G
o and Q205L-G
o (Fig. 2, lower
right panel).
|
|
We next determined whether the chick Rap1GAP has GTPase modulating
activity. For this we transfected PC-12 cells with Rap1GAP and
FLAG-tagged Rap1 (to allow for the examination of Rap1 in transfected
cells). Cells were treated with or without 10 µM
forskolin to activate Rap1 (16). Whole cell lysates were prepared,
incubated with Gst-RalGDS, which binds the GTP-bound form of Rap1 (12), and exposed to glutathione beads. Material adsorbed onto the beads was
resolved by SDS-polyacrylamide gel electrophoresis and blotted with
M2-FLAG antibody. When Rap1GAP cDNA was not used in the
transfection, forskolin-dependent activation of Rap could
be readily observed (Fig. 3, lanes
1 and 2) as previously demonstrated in these cells (16). However, when Rap1GAP was also used in the transfection no
activation of Rap1 was observed (Fig. 3, lanes 3 and
4). We next determined whether G
o regulated
the Rap1GAP modulation of Rap1 activity. Cells were transfected with
wild type or Q205L-G
o with the Rap1GAP, and FLAG-tagged
Rap1. Cells were treated with forskolin to activate Rap1. When
G
o was used, even without forskolin, Rap1 activation was
observed (Fig. 3, lane 5), presumably because G
o binds the transfected as well as the endogenous
Rap1GAP inactivating it, thus allowing Rap1 activation. The addition of
forskolin did not yield any further activation (Fig. 3, lane
6), which suggests that endogenous Rap1GAP may be essential to
regulate Rap1 activity. In contrast, when Q205L-G
o was
used, activated Rap1 was inhibited under basal conditions and was not
stimulated even by incubation with forskolin (Fig. 3, lanes
7 and 8). This finding may result from the inhibition
of adenylyl cyclase by the activated form of G
o or some
other unrecognized G
o signaling pathway. The experiments shown in Fig. 3 indicate that inactive but not activated
G
o can facilitate the activation of Rap1 by sequestering
Rap1GAP.
|
Because it is known that Rap1 regulates the activity of B-Raf and that
B-Raf can regulate the activation state of MAPK1/2 (16), we next
examined the effect of both wild type G
o and Q205L-G
o on MAPK signaling. For this determination,
PC-12 cells were transfected with FLAG-tagged MAPK2 with and without
Rap1GAP, G
o, or Q205L-G
o and then exposed
to NGF to activate MAPK. When cells were treated with NGF, activation
of MAPK2 was observed (Fig. 4,
lanes 1 and 2) as had previously been
demonstrated (17). When Rap1GAP was expressed, stimulation of MAPK2 by
NGF was not observed (Fig. 4, lanes 7 and 8),
indicating that the activation of MAPK2 is dependent on Rap1. When wild
type G
o was expressed, there was a basal activation
state of MAPK2 that could not be potentiated by NGF treatment (Fig. 4,
lanes 3 and 4). However, when
Q205L-G
o was expressed, MAPK2 activation by NGF was
inhibited (Fig. 4, lanes 5 and 6), which is in
agreement with the activation state of Rap1 (see Fig. 3). These data
support the idea that unactivated G
o but not activated
G
o is able to sequester Rap1GAP, thus regulating Rap1
signaling leading to an increase in the activated state of MAPK2.
|
| |
DISCUSSION |
|---|
|
|
|---|
The studies described here show that G
o in its
unactivated state can selectively interact with Rap1GAP. The region of
Rap1GAP involved in interaction with G
o is currently not
known. However, the N terminus of Rap1GAP is highly conserved between
the chicken and human sequence, and in fact all of the independent
two-hybrid clones for chicken Rap1GAP contained the entire N terminus.
This finding is intriguing because the N-terminal 35 amino acids of Rap1GAP are highly similar to regions conserved in two other G
interacting proteins: LGN, a G
i-2 interacting protein
(18), and PCP-2, a guanine nucleotide exchange factor for
G
o (19). This similarity suggests that the N terminus of
Rap1GAP may be the region that interacts with G
o and
that this conserved domain may be used by proteins to interact
specifically with G
i family subunits.
This interaction between G
o and Rap1GAP results in the
sequestration of Rap1GAP such that the levels of activated Rap1
increases. Thus, one might envisage that activation of Go
would lead to the inhibition of Rap and consequently of Rap-mediated
signaling. Thus, Go like Gi would be able to
negatively modulate signaling by the cAMP pathway, but for
Go this would occur at the level of Rap. In contrast to our
current cannonical model of G protein regulation of intracellular
signaling, we propose that G
o does so in a hitherto
unrecognized manner. Rather than the activated form of
G
o binding to and regulating an effector, it is the
inactive form that binds an inhibitory protein (Rap1GAP). Activation of G
o would release Rap1GAP, which then would be free to
inhibit the activity of Rap. Although this mechanism is quite the
opposite of the manner in which other heterotrimeric G protein subunits regulate signal flow, it is not entirely implausible. First,
G
o is the most abundant of the G protein
subunits
and is particularly abundant in the brain, as is Rap1GAP (15); hence,
it is possible that there is enough G
o such that part of
it can be used to sequester Rap1GAP. Second, Go is most
often coupled to inhibitory receptors such as the
2-adrenergic (20) and opiate receptors (21) in the
brain. Activation of these receptors results in the inhibition of cAMP
signaling, because cAMP is capable of activating Rap via both protein
kinase A and the newly discovered exchange factors that directly bind
cAMP (22, 23). Interestingly, forskolin's activation of Rap1, but not
that of G
o, was blocked by protein kinase A inhibitor
(PKI; data not shown). G
o may be able to antagonize cAMP-dependent gene expression, especially signals routed
through the Rap1
B-Raf
MAPK1/2 pathway (24), in neurons by
interacting with Rap1GAP. The experiments shown in Fig. 4 support such
a mechanism of regulation. Thus Go-coupled receptors could
gate signal flow through the Rap1 to B-Raf pathway (25, 26). The
physiological significance remains to be determined.
This interaction of G
o with Rap1GAP is not likely to
explain all of the biological actions of G
o. Activated
G
o has been shown to trigger neurite outgrowth in
neuronal cells (27). Although activated Rap1 can induce neurites in
PC-12 cells (16), Rap1 activation was not detected in this study using
activated G
o. Therefore, it does not appear feasible
that the effects on Rap will explain how activated G
o
stimulates neurite outgrowth nor its reported regulation of tyrosine
kinases in chick dorsal root ganglion neurons (10). Other studies in
our laboratory indicate that in NIH-3T3 cells, Q205L-G
o
activates Stat-3 via Src.2 The
relevance of this pathway in neuronal cells is currently not known. The
search for direct effectors regulated by activated G
o continues.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants GM-54508 and DK-38671 (to R. I.) and CA-72971 (to P. J. S. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF151967, AF151968, AF151734, and AF151966.
§ Supported by the Medical Scientist Training Program and currently by a predoctoral National Research Service Award (F-30 DA05798) from the National Institute on Drug Abuse. To whom correspondence should be addressed: Dept. of Pharmacology, Box 1215, Mount Sinai School of Medicine, One Gustave Levy Pl., New York, NY 10029. Tel.: 212-659-1708; Fax: 212-831-0114; E-mail: jj@doc.mssm.edu.
2 P. T. Ram, C. M. Horvath, and R. Iyengar, submitted for publication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
Rap1GAP, Rap1
GTPase-activating protein;
CPRG, chlorophenol
red-
-D-galactopyranoside;
HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid;
PAGE, polyacrylamide gel electrophoresis;
HRP, horseradish peroxidase;
PBS, phosphate-buffered saline;
MAPK, mitogen-activated protein kinase;
NGF, nerve growth factor;
RGS, regulators of G protein signaling;
RalGDS, Ral GDP dissociation stimulator.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Fung, B. K.,
Hurley, J. B.,
and Stryer, L.
(1981)
Proc. Natl. Acad. Sci. U. S. A.
78,
152-156 |
| 2. | Logothetis, D. E., Kurachi, Y., Galper, J., Neer, E. J., and Clapham, D. E. (1987) Nature 325, 321-326[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Simon, M. I.,
Strathmann, M. P.,
and Gautam, N.
(1991)
Science
252,
802-808 |
| 4. | Smit, M. J., and Iyengar, R. (1998) in Advances in Second Messenger and Phosphoprotein Research (Cooper, D. M. F., ed) , pp. 1-21, Lippincott-Raven Publishers, Philadelphia |
| 5. | Morris, A. J., and Scarlata, S. (1997) Biochem. Pharmacol. 54, 429-435[CrossRef][Medline] [Order article via Infotrieve] |
| 6. | Hildebrandt, J. D., Sekura, R. D., Codina, J., Iyengar, R., Manclark, C. R., and Birnbaumer, L. (1983) Nature 302, 706-709[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Taussig, R.,
Iniguez-Lluhi, J. A.,
and Gilman, A. G.
(1993)
Science
261,
218-221 |
| 8. |
Sternweis, P. C.,
and Robishaw, J. D.
(1984)
J. Biol. Chem.
259,
13806-13813 |
| 9. |
Neer, E. J.,
Lok, J. M.,
and Wolf, L. G.
(1984)
J. Biol. Chem.
259,
14222-14229 |
| 10. |
Diverse-Pierluissi, M.,
Remmers, A. E.,
Neubig, R. R.,
and Dunlap, K.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
5417-5421 |
| 11. | Vidal, M. (1997) in The Yeast Two-hybrid System (Bartel, P. L. , and Fields, S., eds) , pp. 109-147, Oxford University Press, New York |
| 12. | Franke, B., Akkerman, J. W., and Bos, J. L. (1997) EMBO J. 16, 252-259[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Glick, J. L.,
Meigs, T. E.,
Miron, A.,
and Casey, P. J.
(1998)
J. Biol. Chem.
273,
26008-26013 |
| 14. |
Wang, J.,
Ducret, A.,
Tu, Y.,
Kozasa, T.,
Aebersold, R.,
and Ross, E. M.
(1998)
J. Biol. Chem.
273,
26014-26025 |
| 15. | Rubinfeld, B., Munemitsu, S., Clark, R., Conroy, L., Watt, K., Crosier, W. J., McCormick, F., and Polakis, P. (1991) Cell 65, 1033-1042[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Vossler, M. R., Yao, H., York, R. D., Pan, M. G., Rim, C. S., and Stork, P. J. (1997) Cell 89, 73-82[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | York, R. D., Yao, H., Dillon, T., Ellig, C. L., Eckert, S. P., McCleskey, E. W., and Stork, P. J. (1998) Nature 392, 622-626[CrossRef][Medline] [Order article via Infotrieve] |
| 18. | Mochizuki, N., Cho, G., Wen, B., and Insel, P. A. (1996) Gene (Amst.) 181, 39-43[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Luo, Y.,
and Denker, B. M.
(1999)
J. Biol. Chem.
274,
10685-10688 |
| 20. | Diverse-Pierluissi, M., Goldsmith, P. K., and Dunlap, K. (1995) Neuron 14, 191-200[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Moises, H. C., Rusin, K. I., and Macdonald, R. L. (1994) J. Neurosci. 14, 3842-3851[Abstract] |
| 22. |
Kawasaki, H.,
Springett, G. M.,
Mochizuki, N.,
Toki, S.,
Nakaya, M.,
Matsuda, M.,
Housman, D. E.,
and Graybiel, A. M.
(1998)
Science
282,
2275-2279 |
| 23. | de Rooij, J., Zwartkruis, F. J., Verheijen, M. H., Cool, R. H., Nijman, S. M., Wittinghofer, A., and Bos, J. L. (1998) Nature 396, 474-477[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Impey, S., Obrietan, K., and Storm, D. R. (1999) Neuron 23, 11-14[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Iyengar, R. (1996) Science 271, 461-463[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Jordan, J. D., and Iyengar, R. (1998) Biochem. Pharmacol. 55, 1347-1352[CrossRef][Medline] [Order article via Infotrieve] |
| 27. | Strittmatter, S. M., Fishman, M. C., and Zhu, X. P. (1994) J. Neurosci. 14, 2327-2338[Abstract] |
This article has been cited by other articles:
![]() |
R. Zhang, Y. Lin, and C.-T. Zhang Greglist: a database listing potential G-quadruplex regulated genes Nucleic Acids Res., January 11, 2008; 36(suppl_1): D372 - D376. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, J. Yan, P. De, H.-C. Chang, A. Yamauchi, K. W. Christopherson II, N. C. Paranavitana, X. Peng, C. Kim, V. Munugulavadla, et al. Rap1a Null Mice Have Altered Myeloid Cell Functions Suggesting Distinct Roles for the Closely Related Rap1a and 1b Proteins J. Immunol., December 15, 2007; 179(12): 8322 - 8331. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, Y.-c. Tan, G. E. Kreitzer, Y. Nakai, D. Shan, Y. Zheng, and X.-Y. Huang G Proteins G12 and G13 Control the Dynamic Turnover of Growth Factor-induced Dorsal Ruffles J. Biol. Chem., October 27, 2006; 281(43): 32660 - 32667. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. He, I. Gomes, T. Nguyen, G. Jayaram, P. T. Ram, L. A. Devi, and R. Iyengar The G{alpha}o/i-coupled Cannabinoid Receptor-mediated Neurite Outgrowth Involves Rap Regulation of Src and Stat3 J. Biol. Chem., September 30, 2005; 280(39): 33426 - 33434. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Le-Niculescu, I. Niesman, T. Fischer, L. DeVries, and M. G. Farquhar Identification and Characterization of GIV, a Novel G{alpha}i/s -interacting Protein Found on COPI, Endoplasmic Reticulum-Golgi Transport Vesicles J. Biol. Chem., June 10, 2005; 280(23): 22012 - 22020. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Fernandez, F Sanchez-Franco, N Palacios, I Sanchez, and L Cacicedo IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1 J. Mol. Endocrinol., June 1, 2005; 34(3): 699 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Schultess, O. Danielewski, and A. P. Smolenski Rap1GAP2 is a new GTPase-activating protein of Rap1 expressed in human platelets Blood, April 15, 2005; 105(8): 3185 - 3192. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Jordan, J. C. He, N. J. Eungdamrong, I. Gomes, W. Ali, T. Nguyen, T. G. Bivona, M. R. Philips, L. A. Devi, and R. Iyengar Cannabinoid Receptor-induced Neurite Outgrowth Is Mediated by Rap1 Activation through G{alpha}o/i-triggered Proteasomal Degradation of Rap1GAPII J. Biol. Chem., March 25, 2005; 280(12): 11413 - 11421. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dhingra, E. Faurobert, N. Dascal, P. Sterling, and N. Vardi A Retinal-Specific Regulator of G-Protein Signaling Interacts with G{alpha}o and Accelerates an Expressed Metabotropic Glutamate Receptor 6 Cascade J. Neurosci., June 23, 2004; 24(25): 5684 - 5693. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Tsygankova, E. Feshchenko, P. S. Klein, and J. L. Meinkoth Thyroid-stimulating Hormone/cAMP and Glycogen Synthase Kinase 3{beta} Elicit Opposing Effects on Rap1GAP Stability J. Biol. Chem., February 13, 2004; 279(7): 5501 - 5507. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Cabrera-Vera, J. Vanhauwe, T. O. Thomas, M. Medkova, A. Preininger, M. R. Mazzoni, and H. E. Hamm Insights into G Protein Structure, Function, and Regulation Endocr. Rev., December 1, 2003; 24(6): 765 - 781. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fischer, L. De Vries, T. Meerloo, and M. G. Farquhar Promotion of G{alpha}i3 subunit down-regulation by GIPN, a putative E3 ubiquitin ligase that interacts with RGS-GAIP PNAS, July 8, 2003; 100(14): 8270 - 8275. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Witherow, S. C. Tovey, Q. Wang, G. B. Willars, and V. Z. Slepak G{beta}5{middle dot}RGS7 Inhibits G{alpha}q-mediated Signaling via a Direct Protein-Protein Interaction J. Biol. Chem., May 30, 2003; 278(23): 21307 - 21313. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. G. Tall, A. M. Krumins, and A. G. Gilman Mammalian Ric-8A (Synembryn) Is a Heterotrimeric Galpha Protein Guanine Nucleotide Exchange Factor J. Biol. Chem., February 28, 2003; 278(10): 8356 - 8362. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Norum, K. Hart, and F. O. Levy Ras-dependent ERK Activation by the Human Gs-coupled Serotonin Receptors 5-HT4(b) and 5-HT7(a) J. Biol. Chem., January 24, 2003; 278(5): 3098 - 3104. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ribas, A. Takesono, M. Sato, J. D. Hildebrandt, and S. M. Lanier Pertussis Toxin-insensitive Activation of the Heterotrimeric G-proteins Gi/Go by the NG108-15 G-protein Activator J. Biol. Chem., December 20, 2002; 277(52): 50223 - 50225. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Meng and P. J. Casey Activation of Gz Attenuates Rap1-mediated Differentiation of PC12 Cells J. Biol. Chem., November 1, 2002; 277(45): 43417 - 43424. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Banihashemi and P. R. Albert Dopamine-D2S Receptor Inhibition of Calcium Influx, Adenylyl Cyclase, and Mitogen-Activated Protein Kinase in Pituitary Cells: Distinct G{alpha} and G{beta}{gamma} Requirements Mol. Endocrinol., October 1, 2002; 16(10): 2393 - 2404. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Vanhauwe, T. O. Thomas, R. D. Minshall, C. Tiruppathi, A. Li, A. Gilchrist, E.-j. Yoon, A. B. Malik, and H. E. Hamm Thrombin Receptors Activate Go Proteins in Endothelial Cells to Regulate Intracellular Calcium and Cell Shape Changes J. Biol. Chem., September 6, 2002; 277(37): 34143 - 34149. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Woulfe, H. Jiang, R. Mortensen, J. Yang, and L. F. Brass Activation of Rap1B by Gi Family Members in Platelets J. Biol. Chem., June 21, 2002; 277(26): 23382 - 23390. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Brinkmann, O. Daumke, U. Herbrand, D. Kuhlmann, P. Stege, M. R. Ahmadian, and A. Wittinghofer Rap-specific GTPase Activating Protein follows an Alternative Mechanism J. Biol. Chem., April 5, 2002; 277(15): 12525 - 12531. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. K. Peterson, S. Hazard III, S. G. Graber, and S. M. Lanier Identification of Structural Features in the G-protein Regulatory Motif Required for Regulation of Heterotrimeric G-proteins J. Biol. Chem., February 22, 2002; 277(9): 6767 - 6770. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Garcia, J. de Gunzburg, A. Eychène, S. Gisselbrecht, and F. Porteu Thrombopoietin-Mediated Sustained Activation of Extracellular Signal-Regulated Kinase in UT7-Mpl Cells Requires Both Ras-Raf-1- and Rap1-B-Raf-Dependent Pathways Mol. Cell. Biol., April 15, 2001; 21(8): 2659 - 2670. [Abstract] [Full Text] |
||||
|
|